Who
Timothy A. Springer
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Tectonic Therapeutic; Director and 10% owner, Cartesian Therapeutics; Director and 10% owner, Morphic Holding; Director and 10% owner, Scholar Rock Holding.
In numbers
- Trades disclosed
- 228
- Buys
- 78
- Sells
- 0
- Bought
- $217.1M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 17 May 2017
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 11 Apr 2025filed 11 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $155K9,478 at $16.31 | filing |
| 11 Apr 2025filed 11 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $876K53,706 at $16.31 | filing |
| 11 Apr 2025filed 11 Apr 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Bought | $69K6,412 at $10.77 | filing |
| 11 Apr 2025filed 11 Apr 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Bought | $391K36,338 at $10.77 | filing |
| 10 Apr 2025filed 11 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $135K8,092 at $16.73 | filing |
| 10 Apr 2025filed 11 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $767K45,858 at $16.73 | filing |
| 10 Apr 2025filed 11 Apr 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Bought | $83K7,966 at $10.43 | filing |
| 10 Apr 2025filed 11 Apr 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,650609 at $10.92 | filing |
| 10 Apr 2025filed 11 Apr 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Bought | $471K45,144 at $10.43 | filing |
| 10 Apr 2025filed 11 Apr 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Bought | $38K3,451 at $10.92 | filing |
| 9 Apr 2025filed 11 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $42K2,861 at $14.62 | filing |
| 9 Apr 2025filed 11 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $13K857 at $15.23 | filing |
| 9 Apr 2025filed 11 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $237K16,215 at $14.62 | filing |
News
Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Timothy A. Springer; 1 article from the last 14 days about the 3 companies they traded most, at most three about any one of them.